Mereo BioPharma pens $50M Ultragenyx deal for rare bone disease drug

Retrieved on: 2020-12-18 14:03:45

Tags for this article:

Musculoskeletal system

Branches of biology

Monoclonal antibodies

Sclerostin

Osteogenesis imperfecta

Ossification

Emil Kakkis

Click the tags to see associated articles and topics

Mereo BioPharma pens $50M Ultragenyx deal for rare bone disease drug. View article details on hiswai:

Excerpt

Mereo <b>BioPharma</b> is teaming up with Ultragenyx to work on its rare genetic bone disease drug. Worth $50 million upfront and with modest biobucks of ...

Article found on: www.fiercebiotech.com

View Original Article